论文部分内容阅读
1993年4月~1994年9月间,作者用济南假单胞菌苗注射液(商品名佳代胞,简称PVI)胸腔内注射治疗恶性胸膜腔积液,并进行了前瞻性多中心研究。在509例接受PVI治疗的病人中,肺癌合并胸膜腔积液者382例、乳腺癌54例、淋巴瘤16例、其它肿瘤57例,总有效率为82.7%(421/509)。在对照组41例接受顺铂治疗的病人中,肺癌31例,乳腺癌6例,其它肿瘤4例,总有效率为61.0%(25/41)。PVI组的主要不良反应以发热和局部疼痛为主,而顺铂组的主要不良反应则是恶心、呕吐及骨髓抑制。
Between April 1993 and September 1994, the author used intrapleural injection of Jinan Pseudomonas injection (trade name Jiadaiyin, abbreviated as PVI) to treat malignant pleural effusions and conducted a prospective multicenter study. Among 509 patients who received PVI therapy, 382 patients had lung pleural effusion, 54 breast cancers, 16 lymphomas, and 57 other tumors. The total effective rate was 82.7% (421/509). Among the 41 patients who received cisplatin in the control group, 31 were lung cancer, 6 were breast cancer, and 4 were other tumors. The total effective rate was 61.0% (25/41). The main adverse reactions in the PVI group were mainly fever and local pain, while the main adverse reactions in the cisplatin group were nausea, vomiting and bone marrow suppression.